Lynnet Koh | Chairman and Chief Executive Officer and Founder

Lynnet Koh, Chairman and Chief Executive Officer and Founder, Targazyme

As founder /CEO, Lynnet has led the company through vision/idea stage to best in class efficacy signal for our first clinical indications (hematopoietic recovery post hematopoietic stem cell transplantations and GVHD), Phase 3 readiness (with an FDA Phase 3 Special Protocol Assessment in place), preclinical POC outcomes for multiple clinical indications in cancer immunotherapy and regenerative medicine. Lynnet has extensive senior/C-level executive experience in biotech, wireless, internet, consumer products' industries with expertise in leading major new product innovations, new product development and commercialization of cutting-edge technologies/products that became game-changers with multi-billion dollar revenues. She has led numerous financial transactions including raising major capital for her various intrapreunerial/entrepreunerial startups, major M&A and licensing deals. Major product innovations include first generation caller ID, wireless systems, VOIP products and novel enzyme products to improve efficacy outcomes and cost of care for cancer immunotherapy, gene therapy, stem cell transplantation and regenerative medicine.


World Orphan Drug Congress USA 2018 - Conference Day One @ 16:00

TZ 101/TZ 102: Transforming cancer patient survival and quality of life outcomes by improving the delivery of therapeutic cells to tumors and sites of inflammation

back to speakers